Pu Er Shi

This research aims to evaluate the safety and effectiveness of TQA2225AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis NASH. It is a randomized, double-blind, placebo-controlled Phase II study designed to assess how well two different doses of this treatment work in managing NASH, a liver condition characterized by fat buildup and inflammation. Participants will receive either 25mg or 50mg of TQA2225AP025 or a matching placebo, given by weekly subcutaneous injections for 48 weeks. The study includes two experimental groups receiving the different doses, and all treatments are administered under blinded conditions to assess the treatment effects accurately. During the study, participants will undergo liver biopsies at the start and after 48 weeks to measure changes in liver condition using the NASH CRN scoring system. Safety will be closely monitored by tracking any adverse events throughout the treatment period. The study is expected to provide detailed information on both the treatment impact on liver health and its safety profile over nearly a year of participation.

Chronic subdural hematoma CSDH is a common neurosurgical condition where fluid collects between layers of the brains protective membranes, causing brain compression and neurological problems. This condition can be life-threatening if severe, and current treatments lack a clear standard due to uncertain long-term outcomes. Researchers are conducting a multicenter randomized trial to compare two surgical methods to find the best treatment approach for CSDH. The study compares neuroendoscopy-assisted hematoma drainage to conventional burr-hole drainage. Neuroendoscopy allows surgeons to see and remove the hematoma more thoroughly using a small bone flap and a visualized neuroendoscope, aiming to reduce residual hematoma and recurrence. Burr-hole drainage uses a single hole to irrigate and drain the hematoma. Both procedures involve continuous drainage for up to 48 hours post-surgery or until drainage stops naturally. Participants will be adults aged 18 to 90 with diagnosed CSDH requiring surgery. Researchers will assess recurrence rates, mortality, neurological function scales, quality of life, complications, drainage time, and hospital stay length over three months after surgery. Follow-up visits occur at Day 0, Day 2, Month 1, and Month 3 to monitor outcomes and safety. The total study duration per participant is three months post-operation.